secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0000950170-22-008992
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports Q1 2022 results, cash $118.4M; progresses epetraborole clinical program
--------------------------------------------------------------------------------

- Cash and investments total $118.4M as of March 31, 2022; expects operating runway through mid-2024.
- Upsized IPO raised $79.4M; full exercise of underwriter option added $10.4M in April.
- Phase 2/3 trial enrollment for treatment-refractory MAC lung disease expected to begin H1 2022.
- FDA cleared IND, granted Fast Track, QIDP, and orphan drug designation for epetraborole.
- Appointed Dr. Mel Spigelman and Maggie FitzPatrick to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017022008992/0000950170-22-008992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017022008992/antx-20220510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer